Inovio Pharma (INO) Misses Q4 EPS by $1.13

Go back to Inovio Pharma (INO) Misses Q4 EPS by $1.13

Inovio Pharmaceuticals (INO) PT Lowered to $30 at Oppenheimer

March 2, 2022 12:56 PM EST

Oppenheimer analyst Hartaj Singh lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $30.00 (from $35.00) while maintaining an Outperform rating after the company provided a business and pipeline update to investors on 3/1.

The analyst commented, "While the company reported steady progress, the... More